Antidiabetic Effect of Bifidobacterium animalis TISTR 2591 in a Rat Model of Type 2 Diabetes.

IF 4.4 2区生物学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Probiotics and Antimicrobial Proteins Pub Date : 2024-10-09 DOI:10.1007/s12602-024-10377-2

Wanthanee Hanchang, Sivamoke Dissook, Navinee Wongmanee, Worarat Rojanaverawong, Natthawut Charoenphon, Kamonthip Pakaew, Jaruwan Sitdhipol, Thanaphol Thanagornyothin, Pongsathon Phapugrangkul, Susakul Palakawong Na Ayudthaya, Pennapa Chonpathompikunlert

{"title":"Antidiabetic Effect of Bifidobacterium animalis TISTR 2591 in a Rat Model of Type 2 Diabetes.","authors":"Wanthanee Hanchang, Sivamoke Dissook, Navinee Wongmanee, Worarat Rojanaverawong, Natthawut Charoenphon, Kamonthip Pakaew, Jaruwan Sitdhipol, Thanaphol Thanagornyothin, Pongsathon Phapugrangkul, Susakul Palakawong Na Ayudthaya, Pennapa Chonpathompikunlert","doi":"10.1007/s12602-024-10377-2","DOIUrl":null,"url":null,"abstract":"This study investigated the beneficial effects of probiotic Bifidobacterium animalis TISTR 2591 on the regulation of blood glucose and its possible mechanisms in a rat model of type 2 diabetes. The type 2 diabetic-Sprague Dawley rats were established by the combination of a high-fat diet and a low dose of streptozotocin. After 4 weeks of treatment with 2 × 108 CFU/ml of B. animalis TISTR 2591, fasting blood glucose (FBG), oral glucose tolerance, serum insulin, and pancreatic and hepatic histopathology were determined. Liver lipid accumulation, glycogen content, and gluconeogenic protein expression were evaluated. Oxidative stress and inflammatory status were determined. B. animalis TISTR 2591 significantly reduced FBG levels and improved glucose tolerance and serum insulin in the diabetic rats. Structural damage of the pancreas and liver was ameliorated in the B. animalis TISTR 2591-treated diabetic rats. In addition, significant decreases in hepatic fat accumulation, glycogen content, and phosphoenolpyruvate carboxykinase-1 protein expression were found in the diabetic rats treated with B. animalis TISTR 2591. The diabetic rats showed a significant reduction of inflammation following B. animalis TISTR 2591 supplementation, as demonstrated by decreasing hepatic NF-κB protein expression and serum and liver TNF-α levels. The B. animalis TISTR 2591 significantly decreased MDA levels and increased antioxidant SOD and GPx activities in the diabetic rats. In conclusion, B. animalis TISTR 2591 was shown to be effective in controlling glucose homeostasis and improving glucose tolerance in the diabetic rats. These beneficial activities were attributed to reducing oxidative and inflammatory status and modulating hepatic glucose metabolism.","PeriodicalId":20506,"journal":{"name":"Probiotics and Antimicrobial Proteins","volume":" ","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Probiotics and Antimicrobial Proteins","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s12602-024-10377-2","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This study investigated the beneficial effects of probiotic Bifidobacterium animalis TISTR 2591 on the regulation of blood glucose and its possible mechanisms in a rat model of type 2 diabetes. The type 2 diabetic-Sprague Dawley rats were established by the combination of a high-fat diet and a low dose of streptozotocin. After 4 weeks of treatment with 2 × 10⁸ CFU/ml of B. animalis TISTR 2591, fasting blood glucose (FBG), oral glucose tolerance, serum insulin, and pancreatic and hepatic histopathology were determined. Liver lipid accumulation, glycogen content, and gluconeogenic protein expression were evaluated. Oxidative stress and inflammatory status were determined. B. animalis TISTR 2591 significantly reduced FBG levels and improved glucose tolerance and serum insulin in the diabetic rats. Structural damage of the pancreas and liver was ameliorated in the B. animalis TISTR 2591-treated diabetic rats. In addition, significant decreases in hepatic fat accumulation, glycogen content, and phosphoenolpyruvate carboxykinase-1 protein expression were found in the diabetic rats treated with B. animalis TISTR 2591. The diabetic rats showed a significant reduction of inflammation following B. animalis TISTR 2591 supplementation, as demonstrated by decreasing hepatic NF-κB protein expression and serum and liver TNF-α levels. The B. animalis TISTR 2591 significantly decreased MDA levels and increased antioxidant SOD and GPx activities in the diabetic rats. In conclusion, B. animalis TISTR 2591 was shown to be effective in controlling glucose homeostasis and improving glucose tolerance in the diabetic rats. These beneficial activities were attributed to reducing oxidative and inflammatory status and modulating hepatic glucose metabolism.

查看原文本刊更多论文

动物双歧杆菌 TISTR 2591 在 2 型糖尿病大鼠模型中的抗糖尿病作用

本研究探讨了益生菌动物双歧杆菌 TISTR 2591 对 2 型糖尿病大鼠模型血糖调节的有益作用及其可能机制。2 型糖尿病-Sprague Dawley 大鼠是通过高脂肪饮食和低剂量链脲佐菌素联合治疗建立的。用 2 × 108 CFU/ml 的 B. animalis TISTR 2591 治疗 4 周后，测定空腹血糖 (FBG)、口服葡萄糖耐量、血清胰岛素以及胰腺和肝脏组织病理学。对肝脏脂质积累、糖原含量和糖原蛋白表达进行了评估。还测定了氧化应激和炎症状态。动物芽孢杆菌 TISTR 2591 能显著降低糖尿病大鼠的 FBG 水平，改善糖耐量和血清胰岛素。经 B. animalis TISTR 2591 处理的糖尿病大鼠的胰腺和肝脏结构损伤得到了改善。此外，用 B. animalis TISTR 2591 治疗的糖尿病大鼠的肝脏脂肪堆积、糖原含量和磷酸烯醇丙酮酸羧激酶-1 蛋白表达均明显减少。补充动物芽孢杆菌 TISTR 2591 后，糖尿病大鼠的炎症明显减轻，肝脏 NF-κB 蛋白表达以及血清和肝脏 TNF-α 水平均有所下降。动物芽孢杆菌 TISTR 2591 能显著降低糖尿病大鼠体内的 MDA 水平，提高抗氧化剂 SOD 和 GPx 的活性。总之，动物芽孢杆菌 TISTR 2591 能有效控制糖尿病大鼠的血糖平衡并改善其葡萄糖耐量。这些有益活动归因于降低氧化和炎症状态以及调节肝糖代谢。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Probiotics and Antimicrobial Proteins BIOTECHNOLOGY & APPLIED MICROBIOLOGYMICROB-MICROBIOLOGY

CiteScore

11.30

自引率

6.10%

发文量

140

期刊介绍： Probiotics and Antimicrobial Proteins publishes reviews, original articles, letters and short notes and technical/methodological communications aimed at advancing fundamental knowledge and exploration of the applications of probiotics, natural antimicrobial proteins and their derivatives in biomedical, agricultural, veterinary, food, and cosmetic products. The Journal welcomes fundamental research articles and reports on applications of these microorganisms and substances, and encourages structural studies and studies that correlate the structure and functional properties of antimicrobial proteins.